131 related articles for article (PubMed ID: 36410675)
21. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
22. TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells.
Kim S; You D; Jeong Y; Yu J; Kim SW; Nam SJ; Lee JE
Oncol Rep; 2019 Feb; 41(2):1075-1082. PubMed ID: 30535478
[TBL] [Abstract][Full Text] [Related]
23. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
[TBL] [Abstract][Full Text] [Related]
24. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
25. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
26. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells.
Kim S; Jeon M; Lee JE; Nam SJ
Oncol Rep; 2016 Apr; 35(4):2398-404. PubMed ID: 26780941
[TBL] [Abstract][Full Text] [Related]
27. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
31. Aromatase induction in tamoxifen-resistant breast cancer: Role of phosphoinositide 3-kinase-dependent CREB activation.
Phuong NT; Lim SC; Kim YM; Kang KW
Cancer Lett; 2014 Aug; 351(1):91-9. PubMed ID: 24836190
[TBL] [Abstract][Full Text] [Related]
32. Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
Oh JH; Lee JY; Kim KH; Kim CY; Jeong DS; Cho Y; Nam KT; Kim MH
Cancer Lett; 2020 Dec; 495():145-155. PubMed ID: 32987137
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
34. Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m
Liu X; Gonzalez G; Dai X; Miao W; Yuan J; Huang M; Bade D; Li L; Sun Y; Wang Y
Mol Ther; 2020 Dec; 28(12):2593-2604. PubMed ID: 32956623
[TBL] [Abstract][Full Text] [Related]
35. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
36. Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.
Zhao W; Ma J; Zhang Q; Zhang H; Ma W; Li S; Piao Y; Zhao S; Dai S; Tang D
Cell Biol Int; 2024 Apr; 48(4):496-509. PubMed ID: 38225685
[TBL] [Abstract][Full Text] [Related]
37. Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer.
Jiang C; Zhu Y; Chen H; Lin J; Xie R; Li W; Xue J; Chen L; Chen X; Xu S
Cell Death Dis; 2023 Oct; 14(10):653. PubMed ID: 37803002
[TBL] [Abstract][Full Text] [Related]
38. Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR-mediated epigenetic suppression on VGLL4 by DNMT1.
Zhai J; Jiang JF; Shi L
Kaohsiung J Med Sci; 2023 Mar; 39(3):278-289. PubMed ID: 36606584
[TBL] [Abstract][Full Text] [Related]
39. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
[TBL] [Abstract][Full Text] [Related]
40. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
